Measuring performance in biopharmaceutical product development process: What counts?
by Laura Heinonen
International Journal of Technology Intelligence and Planning (IJTIP), Vol. 5, No. 4, 2009

Abstract: Biopharmaceutical industry is a science-based industry with exceptionally long, expensive and complicated product development processes. Measuring performance in the industry is not a simple task, as the conventional indicators of performance can rarely be used in this context. Young biopharmaceuticals can be defined as cash-burning non-profit companies, which are in continuous need of external finance. This paper describes the performance metrics in different stages of the biopharmaceutical product development process and evaluates the importance of these metrics in attracting investors. The empirical study focuses on Finnish biopharmaceutical companies. The data consists of both interviews and secondary sources.

Online publication date: Sat, 28-Nov-2009

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Intelligence and Planning (IJTIP):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com